Novel homozygous inactivating mutation of the calcium-sensing receptor gene (CASR) in neonatal severe hyperparathyroidism-lack of effect of cinacalcet

Atay, Zeynep; BEREKET, ABDULLAH; HALİLOĞLU, BELMA; ABALI, SAYGIN; Ozdogan, Tutku; Altuncu, Emel; Canaff, Lucie; Vilaca, Tatiane; Wong, Betty; Cole, David; Hendy, Geoffrey; Turan, Serap

doi:10.1016/j.bone.2014.04.010

Novel homozygous inactivating mutation of the calcium-sensing receptor gene (CASR) in neonatal severe hyperparathyroidism-lack of effect of cinacalcet

Atay Z., BEREKET A., HALİLOĞLU B., ABALI S., Ozdogan T., Altuncu E., ...Daha Fazla

BONE, cilt.64, ss.102-107, 2014 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 64
Basım Tarihi: 2014
Doi Numarası: 10.1016/j.bone.2014.04.010
Dergi Adı: BONE
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED)
Sayfa Sayıları: ss.102-107
Anahtar Kelimeler: Neonatal severe hyperparathyroidism, Calcium-sensing receptor, Mutation, Calcimimetic, FAMILIAL HYPOCALCIURIC HYPERCALCEMIA, PAMIDRONATE, RESCUE
Acıbadem Mehmet Ali Aydınlar Üniversitesi Adresli: Hayır

Özet

Background: NSHPT is a life-threatening disorder caused by homozygous inactivating calcium-sensing receptor (CASR) mutations. In some cases, the CaSR allosteric activator, cinacalcet, may reduce serum PTH and calcium levels, but surgery is the treatment of choice.